Kenneth Mahaffey, MD
Cardiovascular Disease · Stanford, CANPI 1659455707
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $360,654 of the $446,536 with a category attached, or 80.8%. 18 manufacturers reported payments, led by Janssen Research & Development, LLC at 44.1% of the total. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $1876.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$197K
- E.r. Squibb & Sons, L.L.C.$81K
- CSL Behring$33K
- Bayer$27K
- Eli Lilly$27K
- Novo Nordisk AS$21K
- plus $63K from 12 others
Across 83 payments — averaging $6378.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$270K
- Novo Nordisk$92K
- Novo Nordisk AS$89K
- Quidel Corporation$40K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$18K
- Sanofi US Services Inc.$17K
- plus $4K from 1 others
What the payments were for
- Consulting fees$360,65481%
- Speaking & faculty fees$21,7635%
- Travel & lodging$59,06613%
- Food & beverage$5,0531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 96 | $196,842 |
| E.r. Squibb & Sons, L.L.C. | 26 | $80,527 |
| CSL Behring | 16 | $32,536 |
| Bayer | 22 | $26,979 |
| Eli Lilly | 6 | $26,600 |
| Novo Nordisk AS | 8 | $20,545 |
| Modernatx, Inc. | 24 | $14,500 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $13,320 |
| AstraZeneca | 7 | $11,902 |
| Johnson & Johnson | 3 | $6,072 |
| Novartis | 3 | $5,020 |
| Regeneron | 1 | $3,570 |
| Janssen Global Services, LLC | 3 | $3,273 |
| Janssen Scientific Affairs, LLC | 4 | $1,988 |
| Sanofi US Services Inc. | 3 | $1,690 |
| Astrazeneca UK Limited | 7 | $1,058 |
| Gilead | 1 | $98 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$33,760
- INVOKANA$29,836
- Kerendia$18,213
- EPANOVA$12,823
- Non-Covered$5,363
- Moderna Covid-19 Vaccine$4,000
- PRALUENT$3,570
- EFPEGLENATIDE$1,690
- XARELTO$443
- ENTRESTO$101
How this compares
$446,536 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Praluent PenAlirocumab | 13 | $6,044 |
| Ezetimibe | 18 | $809 |
| Metoprolol Succinate | 21 | $409 |
| Atorvastatin Calcium | 29 | $324 |
| ClopidogrelClopidogrel Bisulfate | 14 | $163 |
| Rosuvastatin Calcium | 16 | $103 |
| Losartan Potassium | 31 | $80 |
| Diltiazem 24hr ErDiltiazem Hcl | 13 | $49 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Stanford
- Wilber SuStanford$1.1M
- Euan AshleyStanford$508K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.